Etavopivat is under clinical development by Forma Therapeutics and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase II drugs for Beta Thalassaemia have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Etavopivat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Etavopivat (FT-4202) is under development for the treatment of sickle cell disease, beta thalassemia and anemia with low risk myelodysplastic syndrome. The drug candidate is administered through oral route as tablet. It acts by targeting pyruvate kinase (PKR) enzyme.
Forma Therapeutics overview
Forma Therapeutics (Forma) is a biotech company. It develops technologies to identify the initial molecules that provide drug discovery program. It offers research in the areas of tumor metabolism, protein homeostasis, epigenetics, and protein-protein interactions. FORMA’s drug development process includes computational and medicinal chemistry, parallel synthesis, X-ray crystallography, and relevant biology studies. The company collaborates with biotechnology companies, pharmaceuticals and biomedicine companies and research institutes for its research and development activities. It operates offices in Watertown and Branford, the US. FORMA is headquartered in Watertown, Massachusetts, the US.
For a complete picture of Etavopivat’s drug-specific PTSR and LoA scores, buy the report here.